FDA left no doubt after a May meeting that it plans to continue pressuring sponsors of erythropoiesis-stimulating agents for more definitive clinical data.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Experts call for active surveillance of drug safety
Billion dollar babies—biotech drugs as blockbusters
Web links
Rights and permissions
About this article
Cite this article
Fox, J. FDA likely to further restrict erythropoietin use for cancer patients. Nat Biotechnol 25, 607–608 (2007). https://doi.org/10.1038/nbt0607-607
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0607-607
This article is cited by
-
Amgen trumps Roche
Nature Biotechnology (2010)
-
Erythropoietins locked into risk management program
Nature Biotechnology (2010)
-
Amgen's Japan deal
Nature Biotechnology (2008)
-
Can 'double blockbuster' strengthen Amgen's backbone?
Nature Biotechnology (2008)
-
News in brief
Nature Biotechnology (2007)
